CAMLINFINE Camlin Fine Q2 FY27 results (Jul–Sep 2026) and concall
Camlin Fine Sciences reported a weak Q2 FY27 characterized by severe working capital constraints, high raw material costs, and unabsorbed fixed overheads in its Aroma division, bringing company-wide EBITDA margin down to 2.5%. In response, the Board approved a Rights Issue of ~INR 250 crores backed by promoters (48% share) to pay down expensive supplier credit and channel financing. Management expects Q3 FY27 to remain constrained before a turnaround in Q4 FY27 to INR 6,000+ million in revenue and 10%+ EBITDA margins.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY27: revenue down 100.0%, net profit down 400.0% against the same quarter last year.
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | Q2 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 10 | 24 | 5 | 8 | 7 −30% | -33 −237% | 16 +220% | 0 −100% |
| EBITDA | 16 | 33 | 5 | 18 | 19 +19% | 6 −82% | 7 +40% | -6 −133% |
| Net profit | -6 | 16 | -11 | -4 | -13 −117% | -6 −137% | -12 −9% | -20 −400% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
